3-bromo-1,2-difluoro-4-nitrobenzene

We are 3-bromo-1,2-difluoro-4-nitrobenzene CAS:350699-92-2 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:   3-bromo-1,2-difluoro-4-nitrobenzene
CAS.NO: 350699-92-2
Synonyms:2-Bromo-3,4-Difluoronitrobenzene;
2-brom-3,4-difluor-1-nitrobenzol;
2-Bromo-3,4-difluoro-1-nitrobenzene;
Molecular Formula: C6H2BrF2NO2
Molecular Weight:237.98600
 
Physical and Chemical Properties:
Density: 1.89 g/cm3
Melting point: /
Boiling point: 226.7ºC at 760 mmHg
Flash point:  90.9ºC
Index of Refraction:1.556
 
Specification:
Appearance: light yellow liquid
Purity:≥98.0%
 
Packing:25kg/drum
Storage:Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.
Application:     used in the Pharmaceutical Industrial

 3-bromo-1,2-difluoro-4-nitrobenzene


Related News: The bulk-buy program, which currently covers 25 types of medicines, allows no more than three successful bidders access to China’s public hospitals, where most Chinese people buy their drugs.3-cloro-p-toluidina CAS:95-74-9 The Company’s immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA.915763-60-9 The Company’s immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA.363-72-4 In the context of increasingly tight global productive capacity cooperation in the pharmaceutical industry, some multinational pharmaceutical companies have chosen to abandon their original full industrial chain model and shift their focus to market operations. R & D, clinical, and production links reduce costs through outsourcing. Patented APIs came into being.In order to seize the highest point of profits, international industry giants have adjusted their development strategies, concentrated their energies on the two ends of the smile curve-research and development and end products, and shifted production links such as intermediates and APIs outward. A division of labor model has been formed.

Related Products
Product Name
(S)-4-(4-(5-(Aminomethyl)-2-oxooxazolidin-3-yl)phenyl)morpholin-3-one View Details
4-Hydroxypyridine View Details
2-Aminobenzenesulfonic acid (1-methylethylidene)di-4,1-phenylene ester View Details
1,1,1-TRIFLUORO-2-BUTANONE Cas:381-88-4 manufacturer 2,2-Difluoro-1,3-benzodioxole manufacturer 4-Fluoro-3-nitrobenzotrifluoride manufacturer (6-phenyldibenzo[b,d]furan-4-yl)boronic acid manufacturer 2-CHLOROLEPIDINE Cas:634-47-9 manufacturer